Doliver Advisors’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.69M | Buy |
4,677
+170
| +4% | +$58.2K | 0.38% | 43 |
|
|
2026
Q1 | $1.59M | Sell |
4,507
-394
| -8% | -$140K | 0.36% | 43 |
|
|
2025
Q4 | $1.6M | Sell |
4,901
-10
| -0.2% | -$3.17K | 0.4% | 43 |
|
|
2025
Q3 | $1.39M | Buy |
4,911
+18
| +0.4% | +$5.22K | 0.36% | 48 |
|
|
2025
Q2 | $1.37M | Sell |
4,893
-5
| -0.1% | -$1.42K | 0.37% | 47 |
|
|
2025
Q1 | $1.53M | Sell |
4,898
-853
| -15% | -$252K | 0.43% | 36 |
|
|
2024
Q4 | $1.5M | Buy |
5,751
+65
| +1% | +$19.3K | 0.42% | 40 |
|
|
2024
Q3 | $1.83M | Sell |
5,686
-431
| -7% | -$141K | 0.5% | 30 |
|
|
2024
Q2 | $1.91M | Sell |
6,117
-331
| -5% | -$97.2K | 0.53% | 25 |
|
|
2024
Q1 | $1.83M | Buy |
6,448
+229
| +4% | +$67K | 0.52% | 25 |
|
|
2023
Q4 | $1.79M | Sell |
6,219
-19
| -0.3% | -$5.18K | 0.55% | 26 |
|
|
2023
Q3 | $1.68M | Sell |
6,238
-6
| -0.1% | -$1.5K | 0.5% | 29 |
|
|
2023
Q2 | $1.39M | Buy |
6,244
+359
| +6% | +$83.3K | 0.42% | 45 |
|
|
2023
Q1 | $1.42M | Buy |
5,885
+1,852
| +46% | +$455K | 0.45% | 34 |
|
|
2022
Q4 | $1.06M | Sell |
4,033
-243
| -6% | -$65.1K | 0.35% | 48 |
|
|
2022
Q3 | $964K | Buy |
4,276
+63
| +1% | +$15.3K | 0.36% | 47 |
|
|
2022
Q2 | $1.02M | Buy |
4,213
+212
| +5% | +$52K | 0.36% | 46 |
|
|
2022
Q1 | $968K | Sell |
4,001
-287
| -7% | -$65.9K | 0.31% | 61 |
|
|
2021
Q4 | $952K | Buy |
4,288
+170
| +4% | +$35.9K | 0.3% | 59 |
|
|
2021
Q3 | $876K | Buy |
4,118
+694
| +20% | +$160K | 0.29% | 66 |
|
|
2021
Q2 | $835K | Buy |
3,424
+814
| +31% | +$200K | 0.28% | 62 |
|
|
2021
Q1 | $649K | Buy |
2,610
+271
| +12% | +$64.7K | 0.24% | 68 |
|
|
2020
Q4 | $538K | Buy |
2,339
+880
| +60% | +$203K | 0.24% | 71 |
|
|
2020
Q3 | $371K | Buy |
1,459
+140
| +11% | +$34.7K | 0.19% | 96 |
|
|
2020
Q2 | $311K | Buy |
1,319
+382
| +41% | +$87.2K | 0.14% | 97 |
|
|
2020
Q1 | $227K | Sell |
937
-435
| -32% | -$95K | 0.11% | 105 |
|
|
2019
Q4 | $331K | Sell |
1,372
-420
| -23% | -$92.6K | 0.13% | 73 |
|
|
2019
Q3 | $367K | Buy |
1,792
+120
| +7% | +$23K | 0.15% | 66 |
|
|
2019
Q2 | $308K | Buy |
+1,672
| New | +$299K | 0.12% | 73 |
|
|
2019
Q1 | – | Sell |
-1,038
| Closed | -$202K | – | 135 |
|
|
2018
Q4 | $202K | Buy |
1,038
+20
| +2% | +$3.9K | 0.1% | 116 |
|
|
2018
Q3 | $211K | Sell |
1,018
-100
| -9% | -$19.7K | 0.09% | 153 |
|
|
2018
Q2 | $207K | Buy |
+1,118
| New | +$198K | 0.09% | 215 |
|
Other funds holding AMGN
Doliver Advisors's AMGN Position: Q2 2026 in Review
Doliver Advisors increased its Amgen (AMGN) stake by 3.8% in Q2 2026, buying an estimated $58.2K and bringing the position to 4,677 shares worth $1.69M. The position accounts for 0.38% of the portfolio, ranked #43.
Doliver Advisors first reported a position in AMGN in Q2 2018 and has held it in 32 quarters since. The position peaked at $1.91M in Q2 2024. 1,543 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.
- Doliver Advisors held 4,677 shares of Amgen worth $1.69M as of Q2 2026.
- Doliver Advisors bought 170 Amgen shares in Q2 2026, an estimated $58.2K.
- Amgen made up 0.38% of Doliver Advisors's portfolio in Q2 2026, its #43 holding.
- Doliver Advisors first reported a position in Amgen in Q2 2018 and has held it in 32 quarters since.
- Doliver Advisors's Amgen position peaked at $1.91M in Q2 2024.
- 1,543 funds tracked by Wall St. Rank held Amgen as of Q2 2026.
Based on Doliver Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.